This article has Open Peer Review reports available.
Role of 14-3-3σ in poor prognosis and in radiation and drug resistance of human pancreatic cancers
- Zhaomin Li†1,
- Zizheng Dong†1,
- David Myer1,
- Michele Yip-Schneider2, 4,
- Jianguo Liu1,
- Ping Cui1,
- C Max Schmidt2, 3, 4 and
- Jian-Ting Zhang1, 4Email author
© Li et al; licensee BioMed Central Ltd. 2010
Received: 22 June 2010
Accepted: 1 November 2010
Published: 1 November 2010
Pancreatic cancer is the fourth leading cause of death in the US. Unlike other solid tumors such as testicular cancer which are now curable, more than 90% of pancreatic cancer patients die due to lack of response to therapy. Recently, the level of 14-3-3σ mRNA was found to be increased in pancreatic cancers and this increased expression may contribute to the failure in treatment of pancreatic cancers. In the present study, we tested this hypothesis.
Western blot analysis was used to determine 14-3-3σ protein level in fresh frozen tissues and was correlated to clinical outcome. A stable cell line expressing 14-3-3σ was established and the effect of 14-3-3σ over-expression on cellular response to radiation and anticancer drugs were tested using SRB assay and clonogenic assays. Cell cycle distribution and apoptosis analyses were performed using propidium iodide staining and PARP cleavage assays.
We found that 14-3-3σ protein level was increased significantly in about 71% (17 of 24) of human pancreatic cancer tissues and that the 14-3-3σ protein level in cancers correlated with lymph node metastasis and poor prognosis. Furthermore, we demonstrated that over-expression of 14-3-3σ in a pancreatic cancer cell line caused resistance to γ-irradiation as well as anticancer drugs by causing resistance to treatment-induced apoptosis and G2/M arrest.
The increased level of 14-3-3σ protein likely contributes to the poor clinical outcome of human pancreatic cancers by causing resistance to radiation and anticancer drugs. Thus, 14-3-3σ may serve as a prognosis marker predicting survival of pancreatic cancer patients and guide the clinical treatment of these patients.
14-3-3σ is a member of a highly conserved family of 14-3-3 proteins that are present in all eukaryotic organisms. There are 7 known human 14-3-3 isotypes (β, γ, ε, η, ζ, σ and τ/θ) [1–3] and they play important roles in many biological activities by binding to and altering the subcellular localization and/or stability of key molecules in various signaling cascades [4, 5]. 14-3-3σ was originally characterized as a human mammary epithelium marker 1  and later rediscovered as an important molecule for cell cycle checkpoint regulation [7, 8].
Recently, proteomic profiling of a drug-selected breast cancer cell line MCF7/AdVp3000 showed that the expression of 14-3-3σ was up-regulated and its expression correlates with the drug resistance level of a series of drug resistant breast cancer cell lines . Further investigation indicated that the elevated expression of 14-3-3σ causes resistance to anticancer drugs by resisting drug-induced apoptosis and inducing cell cycle arrest for repair of DNA damage [9, 10].
Pancreatic cancer is the fourth leading cause of death in the US. Unlike some other cancers such as testicular cancer which are now curable, pancreatic cancer is incurable and more than 90% of pancreatic cancer patients die due to lack of treatment response. 14-3-3σ has been reported to be one of a number of genes that have increased expression at its mRNA level in pancreatic cancer tissues as identified by microarray profiling analyses [11–14]. Thus, it is possible that increased 14-3-3σ expression may contribute to the failure in treatment of pancreatic cancers. In this study, we tested the hypotheses that 14-3-3σ is up-regulated in pancreatic cancers at its protein level and its over-expression may contribute to the failure of treatment of pancreatic cancers by causing resistance to radiation and chemotherapy.
Using fresh-frozen tissues combined with Western blot analysis, we found that 14-3-3σ expression was indeed up-regulated in about 71% of human pancreatic cancer tissues examined and that the 14-3-3σ expression level correlated with lymph node metastasis, consistent with poor prognosis. Furthermore, over-expression of ectopic 14-3-3σ in a pancreatic cancer cell line caused resistance to γ-irradiation as well as anticancer drugs gemcitabine, mitoxantrone and Adriamycin by causing resistance to treatment-induced apoptosis and G2/M arrest.
All studies involving human subjects have been conducted in strict compliance with and approved by the Institutional Review Board (IRB) of Indiana University School of Medicine and its affiliated hospitals. All patients on this study signed informed written consent for collection of pancreatic tissues at the time of routine operation per the Indiana University Pancreas Lesion Tissue Fluid Bank (IUPLTFB) or IU/Lilly Tissue Bank protocol approved by IRB as described above. Surgical pathology was confirmed in all patients. Pancreatic cancer was staged according to the most current AJCC Guidelines. The matching normal tissues were from the farthest point (at least 20 mm) away from lesion (tumor). Tissue specimens were aliquoted and frozen immediately in liquid nitrogen after procurement and stored at -80°C.
Sample preparation and Western blot analysis
Sample preparation and Western blot analysis were performed as previously described . Briefly, the frozen tissues were thawed and homogenized in TNN-SDS buffer (50 mM Tris-HCl, pH value 7.5, 150 mM NaCl, 0.5% Nonidet P-40, 50 mM NaF, 1 mM sodium orthovanadate, 1 mM dithiothreitol, 0.1% SDS, and 2 mM phenylmethylsulfonyl fluoride) by using pellet pestle (Fisher scientific) and the lysates were clarified by centrifugation (12,000 g for 30 min at 4°C).
The tissue or cell lysates were separated by SDS-PAGE and transferred to a PVDF membrane followed by a 2-hr incubation in blocking solution (Tris- or PBS-buffered saline containing 5% nonfat dried milk and 0.1% Tween 20) and a 2-hr incubation with monoclonal antibody against 14-3-3σ (Upstate, NY. 1:500 dilution). The antibody reaction was detected by horseradish peroxidase-conjugated anti-mouse IgG antibody and visualized using ECL. The relative intensity of the protein on Western blot was measured using AlphaEaseFC Analysis tools (Alpha Innotech).
Cell lines and stable transfection
BxPc-3 cells (ATCC) were grown in RPMI1640 (Cellgro) supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin/streptomycin mixture (BioWhittaker). MiaPaCa-2 cells (ATCC) were maintained in DMEM supplemented with 10% fetal bovine serum, 2.5% donor equine serum (HyClone), and 1% penicillin/streptomycin mixture.
The cDNA of 14-3-3σ was engineered into pcDNA3.1(+) (Invitrogen). Transfection of this plasmid and its vector control into MiaPaCa-2 cells were performed using Lipofectamine (Invitrogen) and stable clones were selected using 1 mg/ml G418 (Invitrogen) as previously described [9, 10]. The stable clones were maintained in complete DMEM supplemented with 200 μg/ml G418. For survival and apoptosis assays, G418 was removed and the cells were maintained in G418-free medium for one week prior to the assays.
Similarly, the stable siRNA knockdown BxPc-3 cells were generated as previously described [9, 10]. Briefly, BxPc-3 cells were transfected with pSilencer-σ (14-3-3σ shRNA cloned into pSilencer 3.1-H1neo vector) or scrambled shRNA construct [9, 10] using lipofectamine followed by selection first with 100 μg/ml G418 for 3 days and cultured for one week in complete medium in the absence of G418. The cells were then selected with 1 mg/ml G418 for 2 weeks. Individual clones were tested for 14-3-3σ knockdown and positive clones were propagated and maintained in complete RPMI1640 medium.
Cytotoxicity assay was performed as previously described using sulforhodamine B (SRB) colorimetric  and clonogenic  assays. For SRB assay, cells were seeded in 96-well plate at 5000 cells/well and cultured for 24 hours followed by treatment with anticancer drugs such as Adriamycin, mitoxantrone, gemcitabine or γ-irradiation and cultured continuously for 3 days. The culture medium was then aspirated, and the cells were fixed and stained by addition of 0.4% (w/v) SRB (Sigma) in 1% acetic acid solution followed by incubation at room temperature for 20 minutes. Free SRB was removed by washing cells with 1% acetic acid 3 times. The bound SRB was then solubilized with 10 mM Tris-base, and the OD570 nm was determined using a 96-well plate reader (MRX, Dynex Technologies).
For clonogenic assay, cells were seeded in 6-well plate at 100-200 cells/well and cultured for 24 hours followed by irradiation treatment. The cells were then cultured for two weeks before being subjected to fixation and staining with crystal violent (0.005% in 20% methanol) for 30 min. The colonies were counted manually. The radiation enhancement factor was calculated as the ratio of the mean inactivation dose of control cells divided by the mean inactivation dose of 14-3-3σ over-expression and knockdown cells as previously described . A value greater or less than 1 indicates significant radio-sensitization or -resistance, respectively.
Cell cycle analysis
Cell cycle analysis was performed as previously described . Briefly, 5 × 105 cells were seeded in a 10-cm dish and cultured for 24 hours followed by treatments with γ-irradiation (5 Gy) or mitoxantrone (10 nM) and continuing culture for 24 hours (γ-irradiation) or 72 hours (mitoxantrone). The cells were then harvested, washed, and fixed using ethanol followed by staining with propidium iodide and FACS analysis. Cell cycle profiles were determined using CELL Quest and ModiFit programs.
Data analyses were performed with GraphPad Prism (GraphPad Software Inc.) and Excel 2004 (Microsoft, Seattle, WA). Statistical associations between categorical factors were assessed using the Fisher exact test. Survival time was measured from the time of surgery until death or last follow-up (censor date was March 1, 2009). The association of categorical factors with survival was assessed using the Kaplan-Meier method and was analyzed using the log-rank test. Statistical significance was set at p value < 0.05.
14-3-3σ protein level is up-regulated in human pancreatic cancers
Up-regulated 14-3-3σ expression correlates with lymph node metastasis and mortality
Correlation between 14-3-3σ expression and lymph node metastasis
14-3-3σ expression levela
Lymph Node (+)
Lymph Node (-)
Over-expression of 14-3-3σ causes resistance to radiation and anticancer drugs
We next investigated if over-expression of 14-3-3σ causes resistance to the anticancer drugs gemcitabine, mitoxantrone, and Adriamycin. As shown in Figure 5C, the stable 14-3-3σ-over-expressing cells are significantly more resistant to all three anticancer drugs compared with the stable vector-transfected control clone. Thus, ectopic over-expression of 14-3-3σ causes both radiation and drug resistance in MiaPaCa-2 cells.
To verify the above observations, we created a 14-3-3σ knockdown cell clone from BxPc-3 cells (Figure 5D) and tested if knocking down 14-3-3σ would decrease the resistance of BxPc-3 cells to radiation and drug treatment. As shown in Figure 5E and 5F, the stable clone with 14-3-3σ knockdown is significantly less resistant to γ-irradiation (with a radiation enhancement factor of 1.7), as well as to gemcitabine, Adriamycin, and mitoxantrone than the control cells transfected with scrambled control shRNAs. This finding further supports the conclusion that 14-3-3σ over-expression contributes to treatment resistance in pancreatic cancer cells.
14-3-3σ increases cell cycle arrest upon DNA damage
14-3-3σ over-expression causes resistance to treatment-induced apoptosis
We next examined if the increased resistance of the stable 14-3-3σ-over-expressing cells was also due to inhibition of treatment-induced apoptosis. For this purpose, we first examined the population of stable 14-3-3σ-over-expressing and vector-transfected control cells at the subG1 phase following γ-irradiation. As shown in Figure 6B, the stable 14-3-3σ-over-expressing cells clearly have much fewer cells at the subG1 phase compared with the vector-transfected control cells following γ-irradiation.
We next examined the cleavage of PARP, a target substrate of activated caspases, following treatment with γ-irradiation or with the anticancer drug mitoxantrone. As shown in Figure 6C, the cleaved 85-kDa fragment of PARP is produced only in the control vector-transfected cells following γ-irradiation. Production of the 85-kDa fragment by γ-irradiation is apparently inhibited by over-expression of 14-3-3σ. Figure 6D shows that mitoxantrone-induced production of the 85-kDa fragment of PARP is also inhibited by 14-3-3σ over-expression in the stable 14-3-3σ-over-expressing cells compared with the vector-transfected control. Together, these findings suggest that over-expression of 14-3-3σ in pancreatic cancer cells likely causes resistance to DNA-damage induced apoptosis and, thus, resistance to radiation and drug treatments.
In this study, we demonstrated that the 14-3-3σ protein level was increased in a majority of pancreatic cancer tissues studied (~71%) compared to their corresponding normal tissues and that the 14-3-3σ protein level correlated with lymph node metastasis and patient survival. We also showed that the increased expression of 14-3-3σ correlated with poor cellular response to γ-irradiation and anticancer drugs and that stable over-expression of ectopic 14-3-3σ in a human pancreatic cancer cell line, MiaPaCa-2, significantly increased its resistance level to γ-irradiation as well as anticancer drugs in part by causing resistance to the apoptosis induced by the treatments and by arresting cells in G2/M phase.
It has been reported that 14-3-3σ expression is lost or decreased in human cancers of breast [19, 20], liver , vulva , mouth , as well as neuroendocrine tumors , and small and non-small cell lung [25, 26] cancers. This decrease is thought to be due to hypermethylation of the CpG islands of the 14-3-3σ gene [19, 25, 27, 28]. However, recent studies revealed that the loss of 14-3-3σ expression in breast cancers is a sporadic event and that its expression is up-regulated in some breast tumors [29, 30]. From these later studies, it appears that majority of breast cancer cells with basal/myoepithelial phenotype show 14-3-3σ expression whereas some of the breast cancer cells with luminal epithelial cell differentiation show decreased or loss of 14-3-3σ expression. Furthermore, it has also been reported that 14-3-3σ expression is increased in lung cancers , and head and neck squamous cell carcinomas .
In this study, we demonstrated that 14-3-3σ protein was increased significantly in the majority (17 of 24) of paired fresh-frozen pancreatic cancer tissues examined. Previously, it has also been observed that 14-3-3σ is one of the genes with increased expression at the mRNA level in pancreatic cancer tissues using microarray profiling or real time PCR [11–13, 33]. In the study by Friess et al. , a microarray analysis of 5600 human genes in 8 human pancreatic ductal adenocarcinomas and 8 normal tissues showed that 14-3-3σ is one of 120 genes that had increased expression at the mRNA level in cancer compared to normal tissues. Similarly, Iacobuzio-Donahue et al.  reported that 14-3-3σ is one of the genes with increased expression of mRNA in a cDNA microarray profiling study of 17 infiltrating pancreatic cancer tissues compared with 5 normal pancreatic tissues. Using cell lines and methylation specific PCR analysis it was found that the increased expression of 14-3-3σ mRNA in pancreatic cancer cells may be due to hypomethylation of its promoter region. This later observation is interesting since 14-3-3σ in other cancers such as breast cancer is likely to be hypermethylated, resulting in silencing of its expression. Again in a third study, Logsdon et al.  used microarray analysis of 10 pancreatic cancer and 5 normal tissues and found 14-3-3σ among 188 genes that had increased mRNA expression in pancreatic cancer tissues. Using laser capture dissection and real time PCR, Neupane and Korc  compared the mRNA levels of all seven 14-3-3 genes in 3 normal and 5 pancreatic ductal adenocarcinoma tissues and found that 14-3-3σ is the only gene that has significantly higher expression in cancer tissues. However, all the above studies evaluated the expression of 14-3-3σ at its mRNA level. Since the mRNA level does not always predict the protein level, we performed the current study to determine 14-3-3σ protein expression in pancreatic cancers and found that the 14-3-3σ protein level is indeed significantly increased in pancreatic cancers. This observation is consistent with a previous study by Hustinx et al. . Taken together, these studies clearly show that 14-3-3σ expression is increased at both its mRNA and protein levels in pancreatic cancer tissues and the increase may be due to decreased methylation of its promoter.
The finding that the 14-3-3σ protein level is increased in pancreatic cancers is interesting considering that increased 14-3-3σ expression has been shown to cause drug resistance in breast and prostate cancer cell lines [9, 10]. Indeed, we showed that the increased 14-3-3σ expression in pancreatic cancers appears to correlate with lymph node metastasis, a marker of poor prognosis, and poor survival in a post hoc analysis. Furthermore, over-expression of ectopic 14-3-3σ in a pancreatic cancer cell line, MiaPaCa-2, caused resistance to anticancer drugs as well as to γ-irradiation while knocking down its expression in BxPc-3 cells reduced the resistance. Thus, the increased 14-3-3σ expression in pancreatic cancer cells may contribute to the failure in the treatment of human pancreatic cancers. Clearly, a more extensive prospective study with more patient samples is needed to further warrant this conclusion.
Recently, it has also been found that patients with breast carcinomas (both luminal or basal/myoepithelial phenotypes) that have higher cytoplasmic staining of 14-3-3σ also have shorter survival compared with patients whose tumors have lower 14-3-3σ staining . In estrogen receptor positive tumors, the relationship between 14-3-3σ and poor prognosis is even more significant. This later finding is interesting because it has been shown previously that estrogen regulates the stability of 14-3-3σ by affecting its proteosome-mediated degradation . In another study of cyclin B1 expression in breast carcinoma, Suzuki et al. also showed that the expression of cyclin B1 and 14-3-3σ have a positive correlation and predict a poor prognosis . In a third study, it was suggested that 14-3-3σ expression is an independent prognostic marker for poor survival of colorectal cancer patients . In prostate cancers, we previously found an increase in 14-3-3σ expression as tumor progresses . Adenocarcinomas with high Gleason scores (>7) had significantly higher staining intensities and higher percentages of 14-3-3σ immunoreactive cells than adenocarcinomas with low scores (<7). Adenocarcinomas with lymph node metastases had higher percentages of 14-3-3σ expression compared with adenocarcinomas without lymph node metastases. Thus, over-expression of 14-3-3σ may cause resistance to therapies in various cancers. However, it is noteworthy that opposite observations have also been made in endometrial cancer , head and neck cancer , NSCLC , and nasopharyngeal carcinoma  where it was found that the absence or low expression level of 14-3-3σ predicts poor survival. The reason for the difference between these cancers is currently unknown.
Several popular anticancer drugs used for cancer therapy such as mitoxantrone and Adriamycin are topo II inhibitors which exert their anti-neoplastic effects in susceptible cells by inducing apoptosis, mainly through their ability to induce DNA double-strand breaks. Similarly, γ-irradiation also causes apoptosis via inducing double strand DNA breaks. However, radiation has also been suggested to induce cell death via mitotic catastrophe. In response to a DNA double-strand break, cancer cells undergo apoptosis or go into cell cycle arrest for repair of DNA which prevents replication of damaged DNA or aberrant mitosis which leads to mitotic catastrophe and apoptosis, thereby, attenuating the toxic effect of the treatments. 14-3-3σ has been shown to be essential for maintaining G2, G1, S cell cycle arrest following DNA damage by interacting with and negatively regulating cyclin dependent kinase Cdc2, CDK2 and CDK4, which are responsible for cell cycle progression, and prevent mitotic catastrophe and apoptosis [8, 10, 43]. Cells without 14-3-3σ are unable to arrest their cell cycle progression and will undergo mitotic catastrophe and apoptosis following DNA damage . Furthermore, 14-3-3σ interacts and negatively regulates Bax and possibly BAD, two pro-apoptotic proteins that regulate the release of mitochondria apoptogenic factors . Thus, increased 14-3-3σ expression in pancreatic cancer cells likely causes resistance to DNA damage-induced cell death.
Gemcitabine, a commonly used drug for pancreatic cancer treatment, does not cause DNA double strand breaks. However, incorporation of gemcitabine into DNA also causes damage to DNA by generating premature termination of DNA replication. The observation that over-expression of ectopic 14-3-3σ increases while knocking down its expression reduces resistance to gemcitabine, suggests that 14-3-3σ may also play a role in regulating repair of premature terminations.
14-3-3σ expression is clearly up-regulated in the majority of pancreatic cancers and it may play an important role in pancreatic cancer cell response to drug and radiation treatments and, thus, likely contributes to the failure in treatment of pancreatic cancers. 14-3-3σ may serve as a prognosis marker predicting survival of pancreatic cancer patients and help physician make critical treatment decisions. Future studies targeting 14-3-3σ for development of chemosensitizers may help better treat pancreatic cancers in combinational therapy.
- Fu H, Subramanian RR, Masters SC: 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol. 2000, 40: 617-647. 10.1146/annurev.pharmtox.40.1.617.View ArticlePubMedGoogle Scholar
- Berg D, Holzmann C, Riess O: 14-3-3 proteins in the nervous system. Nat Rev Neurosci. 2003, 4 (9): 752-762. 10.1038/nrn1197.View ArticlePubMedGoogle Scholar
- Li Z, Liu J-Y, Zhang J-T: 14-3-3σ, the double-edged sword of human cancers. American Journal of Translational Research. 2009, 1 (4): 326-340.PubMedPubMed CentralGoogle Scholar
- Muslin AJ, Xing H: 14-3-3 proteins: regulation of subcellular localization by molecular interference. Cell Signal. 2000, 12 (11-12): 703-709. 10.1016/S0898-6568(00)00131-5.View ArticlePubMedGoogle Scholar
- van Hemert MJ, Steensma HY, van Heusden GP: 14-3-3 proteins: key regulators of cell division, signalling and apoptosis. Bioessays. 2001, 23 (10): 936-946. 10.1002/bies.1134.View ArticlePubMedGoogle Scholar
- Prasad GL, Valverius EM, McDuffie E, Cooper HL: Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary cells. Cell Growth Differ. 1992, 3 (8): 507-513.PubMedGoogle Scholar
- Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell. 1997, 1 (1): 3-11. 10.1016/S1097-2765(00)80002-7.View ArticlePubMedGoogle Scholar
- Laronga C, Yang HY, Neal C, Lee MH: Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem. 2000, 275 (30): 23106-23112. 10.1074/jbc.M905616199.View ArticlePubMedGoogle Scholar
- Liu Y, Liu H, Han B, Zhang JT: Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res. 2006, 66 (6): 3248-3255. 10.1158/0008-5472.CAN-05-3801.View ArticlePubMedGoogle Scholar
- Han B, Xie H, Chen Q, Zhang JT: Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma. Mol Cancer Ther. 2006, 5 (4): 903-912. 10.1158/1535-7163.MCT-05-0393.View ArticlePubMedGoogle Scholar
- Friess H, Ding J, Kleeff J, Fenkell L, Rosinski JA, Guweidhi A, Reidhaar-Olson JF, Korc M, Hammer J, Buchler MW: Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci. 2003, 60 (6): 1180-1199.PubMedGoogle Scholar
- Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R, Hanash S: Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003, 63 (10): 2649-2657.PubMedGoogle Scholar
- Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, Walter K, Sato N, Parker A, Ashfaq R, et al: Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol. 2003, 162 (4): 1151-1162.View ArticlePubMedPubMed CentralGoogle Scholar
- Guweidhi A, Kleeff J, Giese N, Fitori JE, Ketterer K, Giese T, Buchler MW, Korc M, Friess H: Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis. 2004, 25 (9): 1575-1585. 10.1093/carcin/bgh159.View ArticlePubMedGoogle Scholar
- Liu Z, Dong Z, Yang Z, Chen Q, Pan Y, Yang Y, Cui P, Zhang X, Zhang JT: Role of eIF3a (eIF3 p170) in intestinal cell differentiation and its association with early development. Differentiation. 2007, 75 (7): 652-661. 10.1111/j.1432-0436.2007.00165.x.View ArticlePubMedGoogle Scholar
- Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH: Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods. 1997, 208 (2): 151-158. 10.1016/S0022-1759(97)00137-3.View ArticlePubMedGoogle Scholar
- Xu J, Peng H, Chen Q, Liu Y, Dong Z, Zhang JT: Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity. Cancer Res. 2007, 67 (9): 4373-4381. 10.1158/0008-5472.CAN-06-3169.View ArticlePubMedGoogle Scholar
- Morgan MA, Meirovitz A, Davis MA, Kollar LE, Hassan MC, Lawrence TS: Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells. Transl Oncol. 2008, 1 (1): 36-43.View ArticlePubMedPubMed CentralGoogle Scholar
- Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR, et al: High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. PNAS. 2000, 97 (11): 6049-6054. 10.1073/pnas.100566997.View ArticlePubMedPubMed CentralGoogle Scholar
- Vercoutter-Edouart A-S, Lemoine J, Le Bourhis X, Louis H, Boilly B, Nurcombe V, Revillion F, Peyrat JP, Hondermarck H: Proteomic analysis reveals that 14-3-3sigma Is down-regulated in human breast cancer cells. Cancer Res. 2001, 61 (1): 76-80.PubMedGoogle Scholar
- Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, Kaneto H, Iku S, Ozeki I, Karino Y, et al: Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene. 2000, 19 (46): 5298-5302. 10.1038/sj.onc.1203898.View ArticlePubMedGoogle Scholar
- Gasco M, Sullivan A, Repellin C, Brooks L, Farrell PJ, Tidy JA, Dunne B, Gusterson B, Evans DJ, Crook T: Coincident inactivation of 14-3-3sigma and p16INK4a is an early event in vulval squamous neoplasia. Oncogene. 2002, 21 (12): 1876-1881. 10.1038/sj.onc.1205256.View ArticlePubMedGoogle Scholar
- Gasco M, Bell AK, Heath V, Sullivan A, Smith P, Hiller L, Yulug I, Numico G, Merlano M, Farrell PJ, et al: Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res. 2002, 62 (7): 2072-2076.PubMedGoogle Scholar
- Yatabe Y, Osada H, Tatematsu Y, Mitsudomi T, Takahashi T: Decreased expression of 14-3-3sigma in neuroendocrine tumors is independent of origin and malignant potential. Oncogene. 2002, 21 (54): 8310-8319. 10.1038/sj.onc.1206014.View ArticlePubMedGoogle Scholar
- Osada H, Tatematsu Y, Yatabe Y, Nakagawa T, Konishi H, Harano T, Tezel E, Takada M, Takahashi T: Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers. Oncogene. 2002, 21 (15): 2418-2424. 10.1038/sj.onc.1205303.View ArticlePubMedGoogle Scholar
- Liu Y, Chen Q, Zhang JT: Tumor suppressor gene 14-3-3sigma is down-regulated whereas the proto-oncogene translation elongation factor 1delta is up-regulated in non-small cell lung cancers as identified by proteomic profiling. J Proteome Res. 2004, 3 (4): 728-735. 10.1021/pr034127+.View ArticlePubMedGoogle Scholar
- Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K: Inactivation of the 14-3-3sigma Gene Is Associated with 5' CpG Island Hypermethylation in Human Cancers. Cancer Res. 2000, 60 (16): 4353-4357.PubMedGoogle Scholar
- Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S: Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene. 2001, 20 (26): 3348-3353. 10.1038/sj.onc.1204438.View ArticlePubMedGoogle Scholar
- Benzinger A, Muster N, Koch HB, Yates JR, Hermeking H: Targeted proteomic analysis of 14-3-3sigma, a p53 effector commonly silenced in cancer. Mol Cell Proteomics. 2005, 4 (6): 785-795. 10.1074/mcp.M500021-MCP200. 3View ArticlePubMedGoogle Scholar
- Simpson PT, Gale T, Reis-Filho JS, Jones C, Parry S, Steele D, Cossu A, Budroni M, Palmieri G, Lakhani SR: Distribution and significance of 14-3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. J Pathol. 2004, 202 (3): 274-285. 10.1002/path.1530.View ArticlePubMedGoogle Scholar
- Nakanishi K, Hashizume S, Kato M, Honjoh T, Setoguchi Y, Yasumoto K: Elevated expression levels of the 14-3-3 family of proteins in lung cancer tissues. Hum Antibodies. 1997, 8 (4): 189-194.PubMedGoogle Scholar
- Villaret DB, Wang T, Dillon D, Xu J, Sivam D, Cheever MA, Reed SG: Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope. 2000, 110 (3 Pt 1): 374-381. 10.1097/00005537-200003000-00008.View ArticlePubMedGoogle Scholar
- Neupane D, Korc M: 14-3-3sigma modulates pancreatic cancer cell survival and invasiveness. Clin Cancer Res. 2008, 14 (23): 7614-7623. 10.1158/1078-0432.CCR-08-1366.View ArticlePubMedPubMed CentralGoogle Scholar
- Hustinx SR, Fukushima N, Zahurak ML, Riall TS, Maitra A, Brosens L, Cameron JL, Yeo CJ, Offerhaus GJ, Hruban RH, et al: Expression and prognostic significance of 14-3-3sigma and ERM family protein expression in periampullary neoplasms. Cancer Biol Ther. 2005, 4 (5): 596-601. 10.4161/cbt.4.5.1748.View ArticlePubMedGoogle Scholar
- Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, Ouchi Y, Inoue S: Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature. 2002, 417 (6891): 871-875. 10.1038/nature00826.View ArticlePubMedGoogle Scholar
- Suzuki T, Urano T, Miki Y, Moriya T, Akahira J, Ishida T, Horie K, Inoue S, Sasano H: Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci. 2007, 98 (5): 644-651. 10.1111/j.1349-7006.2007.00444.x.View ArticlePubMedGoogle Scholar
- Perathoner A, Pirkebner D, Brandacher G, Spizzo G, Stadlmann S, Obrist P, Margreiter R, Amberger A: 14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res. 2005, 11 (9): 3274-3279. 10.1158/1078-0432.CCR-04-2207.View ArticlePubMedGoogle Scholar
- Cheng L, Pan CX, Zhang JT, Zhang S, Kinch MS, Li L, Baldridge LA, Wade C, Hu Z, Koch MO, et al: Loss of 14-3-3sigma in prostate cancer and its precursors. Clin Cancer Res. 2004, 10 (9): 3064-3068. 10.1158/1078-0432.CCR-03-0652.View ArticlePubMedGoogle Scholar
- Ito K, Suzuki T, Akahira J, Sakuma M, Saitou S, Okamoto S, Niikura H, Okamura K, Yaegashi N, Sasano H, et al: 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer. Clin Cancer Res. 2005, 11 (20): 7384-7391. 10.1158/1078-0432.CCR-05-0187.View ArticlePubMedGoogle Scholar
- Erovic BM, Pelzmann M, Grasl M, Pammer J, Kornek G, Brannath W, Selzer E, Thurnher D: Mcl-1, vascular endothelial growth factor-R2, and 14-3-3sigma expression might predict primary response against radiotherapy and chemotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Clin Cancer Res. 2005, 11 (24 Pt 1): 8632-8636. 10.1158/1078-0432.CCR-05-1170.View ArticlePubMedGoogle Scholar
- Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de Las Penas R, Sanchez JM, Moran T, Camps C, Massuti B, et al: 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J Clin Oncol. 2005, 23 (36): 9105-9112. 10.1200/JCO.2005.02.2905.View ArticlePubMedGoogle Scholar
- Cheng AL, Huang WG, Chen ZC, Peng F, Zhang PF, Li MY, Li F, Li JL, Li C, Yi H, et al: Identification of Novel Nasopharyngeal Carcinoma Biomarkers by Laser Capture Microdissection and Proteomic Analysis. Clin Cancer Res. 2008, 14 (2): 435-445. 10.1158/1078-0432.CCR-07-1215.View ArticlePubMedGoogle Scholar
- Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B: 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature. 1999, 401 (6753): 616-620. 10.1038/44188.View ArticlePubMedGoogle Scholar
- Samuel T, Weber HO, Rauch P, Verdoodt B, Eppel JT, McShea A, Hermeking H, Funk JO: The G2/M regulator 14-3-3sigma prevents apoptosis through sequestration of Bax. J Biol Chem. 2001, 276 (48): 45201-45206. 10.1074/jbc.M106427200.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/598/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.